Terry A. Wallace

Array ( [id] => 18109587 [patent_doc_number] => 20230002467 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => SUPERAGONISTS, PARTIAL AGONISTS AND ANTAGONISTS OF INTERLEUKIN-2 [patent_app_type] => utility [patent_app_number] => 17/825660 [patent_app_country] => US [patent_app_date] => 2022-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27344 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17825660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18202415 [patent_doc_number] => 11584798 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-21 [patent_title] => High concentration antibody-containing liquid formulation [patent_app_type] => utility [patent_app_number] => 17/752978 [patent_app_country] => US [patent_app_date] => 2022-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 8 [patent_no_of_words] => 7364 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17752978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19387940 [patent_doc_number] => 20240277810 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => INTERFERONS AND NUCLEAR EXPORT INHIBITORS FOR USE IN METHODS OF TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/565700 [patent_app_country] => US [patent_app_date] => 2022-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10788 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18565700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20555373 [patent_doc_number] => 20260055153 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-26 [patent_title] => Development and Use of Novel Interleukin 15 Mutant Polypeptide [patent_app_type] => utility [patent_app_number] => 18/564329 [patent_app_country] => US [patent_app_date] => 2022-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1100 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18564329 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19793354 [patent_doc_number] => 12234284 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-25 [patent_title] => Treatment of kidney injury [patent_app_type] => utility [patent_app_number] => 17/751117 [patent_app_country] => US [patent_app_date] => 2022-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 45 [patent_no_of_words] => 36159 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17751117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18279119 [patent_doc_number] => 20230094591 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => HIGH AFFINITY ANTIBODIES TO HUMAN IL-6 RECEPTOR [patent_app_type] => utility [patent_app_number] => 17/749728 [patent_app_country] => US [patent_app_date] => 2022-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7760 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17749728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19846754 [patent_doc_number] => 20250092105 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => GRANULIN/EPITHELIN MODULES AND COMBINATIONS THEREOF TO TREAT NEURODEGENERATIVE DISEASE [patent_app_type] => utility [patent_app_number] => 18/562241 [patent_app_country] => US [patent_app_date] => 2022-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28633 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18562241 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18018865 [patent_doc_number] => 20220370364 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => HIGH CONCENTRATION FORMULATIONS OF ANTI-CSF1 AND ANTI-CSF1R ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/747844 [patent_app_country] => US [patent_app_date] => 2022-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16769 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17747844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19855571 [patent_doc_number] => 12258394 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-25 [patent_title] => IL-5 antibody, antigen binding fragment thereof, and medical application therefor [patent_app_type] => utility [patent_app_number] => 17/747627 [patent_app_country] => US [patent_app_date] => 2022-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 8 [patent_no_of_words] => 16731 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17747627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19651290 [patent_doc_number] => 12173059 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-24 [patent_title] => LTBP complex-specific inhibitors of TGFb and uses thereof [patent_app_type] => utility [patent_app_number] => 17/746325 [patent_app_country] => US [patent_app_date] => 2022-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 35 [patent_no_of_words] => 115271 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 214 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17746325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19608901 [patent_doc_number] => 12157767 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-03 [patent_title] => Isolation and purification of anti-IL-13 antibodies using protein a affinity chromatography [patent_app_type] => utility [patent_app_number] => 17/745982 [patent_app_country] => US [patent_app_date] => 2022-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 29923 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 290 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17745982 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18536086 [patent_doc_number] => 20230241173 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => COMPOSITIONS AND METHODS FOR REGULATING LEUKOCYTE ADHESION [patent_app_type] => utility [patent_app_number] => 17/745495 [patent_app_country] => US [patent_app_date] => 2022-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30162 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17745495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17851954 [patent_doc_number] => 20220281996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => Compositions and Methods to Regulate Renalase in the Treatment of Cancer [patent_app_type] => utility [patent_app_number] => 17/739691 [patent_app_country] => US [patent_app_date] => 2022-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38771 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17739691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17850491 [patent_doc_number] => 20220280532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/739688 [patent_app_country] => US [patent_app_date] => 2022-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28120 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17739688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18198182 [patent_doc_number] => 20230051701 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => ANTIBODIES AGAINST CD73 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/737403 [patent_app_country] => US [patent_app_date] => 2022-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 81043 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 1 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17737403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318368 [patent_doc_number] => 20240239911 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => TREATMENT FOR LUPUS NEPHRITIS USING ANTI-BAFFR ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/558730 [patent_app_country] => US [patent_app_date] => 2022-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18071 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18558730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19331364 [patent_doc_number] => 20240245794 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => ANTI-CD37 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/288148 [patent_app_country] => US [patent_app_date] => 2022-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35955 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -60 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18288148 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17867100 [patent_doc_number] => 20220289835 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => SAFE AND EFFECTIVE METHOD OF TREATING PSORIASIS WITH ANTI-IL-23 SPECIFIC ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/734482 [patent_app_country] => US [patent_app_date] => 2022-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40997 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17734482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19855578 [patent_doc_number] => 12258401 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-25 [patent_title] => Anti-CD47 combination therapy [patent_app_type] => utility [patent_app_number] => 17/733378 [patent_app_country] => US [patent_app_date] => 2022-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 23 [patent_no_of_words] => 23481 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17733378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20771549 [patent_doc_number] => 12655209 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-16 [patent_title] => FcRn antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/661070 [patent_app_country] => US [patent_app_date] => 2022-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 29 [patent_no_of_words] => 33801 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 232 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17661070 [rel_patent_id] =>[rel_patent_doc_number] =>)